Oric Pharmaceuticals, Inc. — Director's Dealing 2020

Apr 24, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2020-04-23

Reporting Person: Chacko Jacob (Director, President and CEO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Preferred Stock	$		Common Stock (62500)		Direct
Stock Option (right to buy)	$1.60	2028-05-09	Common Stock (850500)		Direct

Footnotes

F1: The Series C Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.

F2: The option is subject to an early exercise provision and is immediately exercisable. One fourth (1/4th) of the shares subject to the option vested on April 30, 2019, and an additional one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.